Genaera (GENR) Misses Q3 EPS by 3c
Genaera Corporation (Nasdaq: GENR) reports a Q3 loss of $0.19, 3 cents worse than estimates. Revenues were $92K vs. consensus of $100K. (only 1 analyst)
The Company's cash, cash equivalents and short-term investment balance was $10.4 million at September 30, 2008.
Genaera Corporation (Genaera) is a biopharmaceutical company dedicated to developing medicines to address substantial unmet medical needs in pharmaceutical markets.[SM]
The Company's cash, cash equivalents and short-term investment balance was $10.4 million at September 30, 2008.
Genaera Corporation (Genaera) is a biopharmaceutical company dedicated to developing medicines to address substantial unmet medical needs in pharmaceutical markets.[SM]
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- Taro Pharmaceutical Industries (TARO) Nearly Doubles Q1 EPS to 1.06
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
